Background-Long-term follow-up after percutaneous mitral commissurotomy enables predictive factors of late results to be identified. Methods and Results-Late results of percutaneous mitral commissurotomy were assessed in 1024 consecutive patients.
P ercutaneous mitral commissurotomy (PMC), the first nonsurgical treatment for valvular disease, 1 has become the reference treatment for mitral stenosis in patients with favorable valvular anatomy. 2, 3 Patient presentation is highly variable between Western and developing countries, where mitral stenosis remains frequent. With growing experience, indications of PMC have been progressively widened to include less favorable conditions. [2] [3] [4] The ability to predict individual patient outcome is therefore of importance in clinical practice. A number of series have reported late results after PMC. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] However, unlike surgical commissurotomy, [17] [18] [19] [20] maximum follow-up for PMC seldom exceeds 10 years. [15] [16] In addition, the number of predictive factors of late results makes it difficult to assess individual patient outcome, which emphasizes the usefulness of validated multivariable models in this setting. Immediate results can be predicted, 21, 22 but no tool currently is available to predict long-term outcome for any given patient. In clinical practice, after PMC, patients wish to receive accurate information regarding their longterm clinical status. Current guidelines do not give specific recommendations for follow-up after PMC.
Clinical Perspective on p 2127
The aim of this study was to analyze the results of PMC up to 20 years in a single-center series comprising patients with diverse characteristics, with a particular focus on the analysis of predictive factors of late functional results after successful PMC. We elaborated a simple scoring system combining the weights of selected variables to provide an individualized assessment of prognosis before discharge, particularly in high-risk patients who need closer follow-up.
Methods

Study Population
The population consisted of a previously described cohort of 1024 consecutive patients residing in France who underwent PMC between March 1986 and March 1995 in our institution. 11 
Technique
All procedures were performed with the antegrade transvenous approach. A single balloon was used in the first 26 patients; a double-balloon was then used in 390. Beginning in October 1990, we systematically used the Inoue balloon in the remaining 608 patients, according to the stepwise technique under echocardiographic monitoring. Contraindications to PMC were detailed previously and correspond to guidelines. 2, 3, 21 
Measurements
Echocardiography was performed in the same laboratory on the day before PMC and 24 to 48 hours after PMC. On the basis of transthoracic echocardiography and fluoroscopy, mitral valve anatomy was classified into 3 groups according to the Cormier classification: flexible valves and mild subvalvular disease (chordae Ն10 mm long; group 1), flexible valves and extensive subvalvular disease (chordae Ͻ10 mm long; group 2), and calcified valves confirmed by fluoroscopy (group 3). 23, 24 The reference measurement for mitral valve area (MVA) was planimetry by 2-dimensional echocardiography. In cases with missing data, Doppler half-time pressure was used. 21 Mean transmitral gradient was assessed by Doppler. The degree of mitral regurgitation was assessed with left ventriculography according to the Sellers classification. In cases of missing data, a semiquantitative evaluation by color Doppler was used. 25 
Follow-Up
Clinical follow-up was based on visits to the department or a standardized questionnaire sent to the patient's cardiologist. Follow-up was concluded in December 2008. Patients were considered lost to follow-up if they did not experience death or intervention and if their last contact was before January 2008. Follow-up was completed for 923 patients (90.1%). Median follow-up was 10.7 years (interquartile range, 4.6 -15.8 years).
End Points
Good immediate results were defined by the usual composite end point combining a final MVA Ն1.5 cm 2 without mitral regurgitation Ͼ2/4. 8, 10, [13] [14] [15] [16] 22 The events taken into account during follow-up were death, need for valvular surgery or repeat PMC, and deterioration in New York Heart Association (NYHA) functional class III or IV. All events were analyzed as time-dependent variables.
Clinical events occurring during follow-up were combined into the following end points: (1) overall survival, (2) survival considering only cardiovascular-related death, (3) survival with no cardiovascular death or intervention (mitral surgery or repeat PMC), and (4) good functional results defined as survival with no cardiovascular death or intervention and in NYHA functional class I or II. Survival status was censored at the time of surgery or repeat dilatation. Any unexplained death was considered to be cardiovascular related.
Statistical Analysis
All data were entered prospectively in a database beginning in 1986. Cumulative survival curves were determined for the 4 end points of late results according to the Kaplan-Meier method. Continuous variables were expressed as meanϮSD, except for follow-up duration, which was expressed as a median and interquartile range. Categorical variables were expressed as percentages and were grouped if needed according to risk progression.
Predictive analysis concerned the predefined end point of poor late functional results and was performed in the 912 patients who had good immediate results of PMC (MVA Ն1.5 cm 2 without mitral regurgitation Ͼ2/4). This population of 912 patients was split into 2 randomly selected cohorts: a derivation cohort of 609 patients used for model building and a validation cohort of 303 patients. Model coefficients were not reestimated in the validation cohort. Univariable analysis was performed with a Cox proportional hazards model for the 12 preprocedure variables, the 2 procedure-related variables, and the 3 postprocedure variables listed in Table 1 . Variables with PϽ0.20 were entered in a multivariable-adjusted Cox proportional hazards model with a backward selection procedure and a significance level of Pϭ0.05. After checking for log-linearity assumptions between covariates and the composite end point, we categorized continuous variables as previously described. 11 Then, 2-way interactions were studied between significant variables in multivariable analysis. When interactions were significant at the level of Pϭ0.01, the combinations of variables were grouped according to homogeneous risk classes. Combinations of variables and isolated covariates were included in the final multivariable-adjusted Cox proportional hazards model and selected by use of a backward selection procedure and a significance level of Pϭ0.05.
A score-based prediction rule for good late functional results was developed from the multivariable model of the derivation cohort. Regression coefficients were multiplied by 3 and rounded to the nearest integer. The score, ranging from 0 to 13, was the sum of the points corresponding to each variable of the multivariable model. Three risk groups were defined by cutoff values according to sample sizes and to ensure a homogeneous risk assessment in each risk group in the validation sample.
The discrimination obtained with the final multivariable model and the score was assessed by use of the overall C index defined as a natural extension of the receiver-operating characteristic area to survival analysis and its 95% confidence interval (CI). 26 Observed rates with their 95% CIs and predicted rates of good functional results were computed and plotted to assess the calibration of the final multivariable model and the score.
Analyses were performed with SAS statistical software (version 9.2; SAS Institute, Cary, NC) and the function concordance index of the R package survcomp. 27 
Results
Whole Population
Patient characteristics of the whole population and of the derivation and validation cohorts are detailed in Table 1 . Of the 1024 patients, severe adverse events were in-hospital death in 4 patients (0.4%), embolic stroke in 3 (0.3%), and severe mitral regurgitation (Sellers grade Ն3/4) in 35 (3.4%). Good immediate results were obtained in 912 patients (89%).
Of the 112 patients with poor immediate results, 80 underwent early mitral surgery with a median duration of 1 month after PMC (interquartile range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Of the 32 nonoperated patients, 22 died (Table 2) .
Of the 912 patients with good immediate results, 351 underwent an intervention on the mitral valve. Mitral valve replacement was performed in 247 patients (70%), conservative mitral surgery in 19 (5%), and repeat PMC in 85 (25%; Table 2 ). After good immediate results, the median duration between PMC and intervention was 8.4 years (interquartile range, 4.9 -12.3).
Twenty-year rates of survival and composite end points are detailed in Table 3 . Kaplan-Meier curves of good functional results are shown in Figure 1 for the overall population and according to the immediate results of PMC. Kaplan-Meier curves of survival and survival without intervention are shown in the online-only Data Supplement.
Predictive Factors of Poor Late Functional Results
Predictive analysis of poor late functional results was performed in the 609 patients of the derivation cohort who had good immediate results of PMC. Twenty-year rates of good late functional results were 43.1Ϯ5.6% in Cormier's echocardiographic group 1, 38.9Ϯ3.1% in group 2, and 15.4Ϯ3.5% in group 3 (PϽ0.0001).
Univariable predictive factors of late functional results are detailed in Table 4 . The 2 procedure-related variables were not predictive of late functional results.
Multivariable analysis without interactions identified 8 independent predictive factors of poor late functional results Female sex, n (%) 848 (83) 496 (81) 259 (85) NYHA functional class, n (%)
II 232 (22) 157 (26) 61 (20) III 745 (73) 430 (70) 228 (75) IV 42 (4) 19 (3) 12 (4) Previous commissurotomy, n (%) † 163 (16) 84 (14) 51 (17) Previous embolism, n (%) 119 (12) 76 (12) 25 (8) Atrial fibrillation, n (%) 408 (40) 232 (38) 120 (40) Cardiothoracic index 51Ϯ6
Valve anatomy, n (%) 1 141 (14) 98 (16) †Good functional results were defined as survival with no cardiovascular death or intervention and in New York Heart Association functional class I or II.
after a good immediate result (Table I in the online-only Data Supplement). After inclusion and selection of interactions, 7 predictive factors were finally identified (Table 5) . Five predictive factors were preprocedure variables (age, sex, NYHA class, rhythm, and valve anatomy), and the 2 others were related to the immediate results of PMC (final MVA and final mean gradient; Figure 2 ). Six of the 7 factors acted through interactions: between age and final MVA after the procedure, between sex and presence of valve calcification, and between rhythm and NYHA class (Table 5) .
For the final multivariable model in the derivation cohort, the overall C index was 0.74 (95% CI, 0.67-0.80). Observed and predicted rates of good functional results at 15 years were 50.1% (95% CI, 46.1-54.6) and 51.8%, respectively.
Score Building
The scoring system was derived from the final multivariable model in the derivation cohort of 609 patients. The score was calculated by adding each component and ranged from 0 to 13 (Table 5 ). Three risk groups were defined: a low-risk group (score of 0 -2), intermediate-risk group (score of 3-5), and high-risk group (score of 6 -13). In the derivation cohort, the low-, intermediate-, and high-risk groups comprised 182 (30.0%), 286 (47.2%), and 138 (22.8%) patients, respectively, and accounted for 48, 153, and 108 events, respectively, during follow-up.
Compared with the low-risk group, hazard ratio related to poor late functional results was 2.8 (95% CI, 2.1-3.9) for the intermediate-risk group (PϽ0.0001) and 7.4 (95% CI, 5.2-10.5) for the high-risk group (PϽ0.0001). The overall C index was 0.79 (95% CI 0.72-0.86) for the score in the derivation cohort. The calibration of the score obtained in the derivation cohort is shown in Table 6 .
Score Validation
The predictive model was validated in the 303 patients of the validation cohort. The low-, intermediate-, and high-risk groups comprised 81 (26.9%), 146 (48.5%), and 74 (24.6%) patients, respectively, and accounted for 28, 78, and 51 events during follow-up.
Predicted good late functional results were 55.1% for group 1, 29.1% for group 2, and 10.5% for group 3 at 20 years ( Figure 3) . The overall C index was 0.71 (95% CI, 0.58 -0.80) for the score in the validation cohort. The good calibration of the score was attested by the fact that predicted rates were within the 95% CI of observed rates of good functional results for the 3 risk groups in the validation cohort ( Figure 3 and Table 6 ).
Discussion
In this series comprising 1024 patients with diverse characteristics and reporting the longest follow-up after PMC, the 20-year rate of good functional results was 30.2Ϯ2.0% in the whole population and 33.3Ϯ2.2% after good immediate results. The multivariable model shows that age, final valve area, and final gradient have a strong impact on late functional results after PMC. The identification of interactions allows a better understanding of the relationships between the independent predictive factors and late functional results of PMC. The high number of events enabled a multivariable model to be developed with an appropriate statistical robustness, thereby enabling the prognostic value of each variable to be accurately identified. Moreover, this is the first time that a predictive model of long-term results of PMC has been validated in a separate sample and a user-friendly scoring system has been derived and validated, aimed at assessing late functional results in any given patient.
Late Results of PMC
The analysis of late results of PMC should take into account patient characteristics because event-free survival rates are higher in series that include younger patients. 12, 14 The only series with a follow-up beyond 15 years reported 42% good functional results at 19 years after good immediate results in young patients with favorable valve anatomy. 16 However, only 18 patients had a follow-up of Ն18 years. Despite the impact of differences in patient characteristics, the 20-year rates of event-free survival of the present series are consistent with those reported after closed-heart commissurotomy. [17] [18] [19] [20] Late outcome is highly dependent on the immediate results of PMC. Poor immediate results are related to insufficient valve opening or severe traumatic mitral regurgitation, leading to early surgery or death in most patients. Conversely, after good immediate results, late functional deterioration is progressive and occurs at a constant rate over time, as shown by the linear decrease of the curve in the present series. Mitral restenosis has been shown to be the main cause of late deterioration after successful PMC. 10, 11, 13, 14 
Predictive Factors of Poor Late Functional Results
As in previous analyses, 11, 28 we chose to restrict the predictive analysis to the patients who had good immediate results to avoid analyzing early events owing to poor immediate results of PMC and progressive deterioration after a successful procedure together. After poor immediate results of PMC, early surgery is needed in most patients, as recommended in guidelines and as shown here. Therefore, the prediction of late functional results is of little interest in these patients. The analysis of a homogeneous mechanism of deterioration, ie, mitral restenosis, is more appropriate to ensure a reliable identification of predictive factors of good late functional results.
The composite end point of late functional results has the advantage of taking into account all clinical consequences of the deterioration of valve function. This end point corresponds to the aim of PMC in clinical practice, which is to prevent cardiovascular death, to avoid intervention on the mitral valve, and to obtain good continuing functional status. This composite end point has been used in most studies of late results after PMC. 8 -10,12,13,15,16 In the present series, final MVA was an important predictor of late functional results, which is consistent with other series. [5] [6] [7] 9, 10, 14 Final MVA was assessed with planimetry, which is considered the reference measurement of MVA. 29 We found that final MVA interacts with age, which is also a strong predictive factor of late functional results of PMC. 8, [13] [14] [15] This interaction shows that the prognostic impact of final MVA is strong in young patients but decreases in older patients and is no longer significant after 70 years of age. Final mean gradient was also an important independent predictor of late results, in accordance with other series. 8,12,13 Unlike final MVA, the impact of final mean gradient on late results did not differ according to age, as shown by the absence of interaction in our series. Thus, both mitral gradient and final MVA have a strong impact on late functional results in young patients, whereas gradient remains the only predictive factor after 70 years of age. The increase in the rigidity of the valvular and subvalvular apparatus in older patients, which has a strong impact on gradient for a given MVA, may contribute to this finding. Valve area has been shown to be variable according to cardiac output when commissures are opened, as is the case after PMC. 30 This accounts for the fact that other indexes of valve stenosis such as mean gradient add to the prognostic value of MVA after PMC. Final mitral gradient as assessed 24 to 48 hours after PMC should therefore be considered in conjunction with final MVA in the evaluation of immediate results of PMC. An advantage of mitral gradient is that its Doppler measurement is easy to perform and reliable. 29 Late functional results are highly dependent on mitral valve function at follow-up, which is determined by valve function early after PMC, as assessed by final MVA and gradient and then by progressive restenosis. Age may influence restenosis because it reflects the duration of heart valve disease and thus contributes to the structural changes of the mitral valve. Mitral valve anatomy has been identified as a predictive factor of late results in a number of series. 5, 8, 9, 12, 13, 15, 16 In the present analysis, the contribution of valve anatomy to the prediction of late results was restricted to the presence of valve calcification in men. Sex differences are frequently encountered in rheumatic heart disease, as attested by the female predominance in series of PMC. 4 -16 However, no impact of sex on the progression of mitral stenosis has been reported so far. Our echocardiographic classification does not take into account the severity and location of valve calcification, which have been shown to influence late outcome. [31] [32] [33] Another explanation for the impact of valve anatomy on late results in certain series is that they also included patients with poor immediate results of PMC in the predictive analysis. [5] [6] [7] [8] [9] [10] 12, 15 Including poor immediate results leads to overestimation of the predictive value of valve anatomy on late results because valve anatomy is a strong predictor of procedural success. 21, 22, 34 A recent series including only good immediate results of PMC did not identify valve anatomy as a significant predictive factor of late functional results in multivariable analysis. 14 The interaction between rhythm and NYHA class shows that a higher initial NYHA class is a predictive factor of poor late functional results only in patients in atrial fibrillation. These variables are closely linked and do not directly reflect mitral valve function but the consequences of mitral stenosis and the evolutive stage of the disease. They have been identified as predictors of poor late functional results in previous series. 6, 9, 13, 15, 16, 35 Comorbidities were not included in this analysis but are not likely to have a significant impact on the composite end point, which does not include death resulting from noncardiovascular causes. In addition, comorbidities are not frequent in patients with mitral stenosis, mainly because of their younger age compared with patients with degenerative valve diseases. 36 The technique used for PMC did not influence late functional results in our series, which is consistent with the findings from a randomized study. 37 
Scoring System
The assessment of individual patient outcome is difficult because of the number of predictive factors, their interactions, and their different predictive strengths, as reflected by adjusted hazard ratios. This is of particular importance in Western countries given the diversity of patient characteristics. The only means to assess individual outcome is to use a simple score combining all multivariable predictive factors of late functional results according to their own predictive strength. 38 The high number of events allowed us to split the population into 2 cohorts to elaborate and validate a scoring system and to assess its performance with methods adapted to time-dependent end points.
The 13-point scoring system enabled 3 risk groups to be defined, with a graded increase in the risk of poor late functional results from the low-risk group (score Յ2) to the high-risk group (score Ն6). This score illustrates the strong predictive value of age and the quality of immediate results, as assessed by valve area and gradient, which together account for 8 of 13 points.
The value of the overall C index of the present scoring system (0.71; 95% CI, 0.58 -0.80) is consistent with the values of C index of 0.72 21 and 0.73 22 obtained with predictive models validated on immediate results of PMC. The good calibration of the score in the validation cohort shows the robustness of the score and is a strong argument in support of its application in clinical practice.
In the validation cohort, excellent long-term results were observed in the low-risk group, which accounted for 30% of the patients with good functional results in 55.1% of the patients at 20 years. In the intermediate-risk group, despite a number of nonideal candidates for PMC, 29.1% of patients experienced sustained functional benefit, enabling valve replacement to be significantly postponed. This is of importance in Western countries, where a number of patients present with nonoptimal characteristics to PMC. Late functional results were poor in patients of the high-risk group, in whom surgery should be considered a first option provided that its risk is not expected to be prohibitive. Although no randomized trial is available for such patients, a comparative analysis suggested that surgery gives better late results than PMC in patients with unfavorable characteristics for PMC. 35 The use of this validated score allows easy assessment of individual prognosis after PMC in current practice before hospital discharge. This score relies on a limited number of easily obtainable variables and is therefore very simple to use at beside in any cardiac unit. Such a score provides an appropriate answer to patient expectations regarding their long-term outcome. In the absence of specific recommendations from the guidelines, this score proposes an individualized follow-up, which is of particular importance for patients in the high-risk group. The high likelihood of poor late outcome in this latter group justifies making practitioners and patients aware of the need for close follow-up. Moreover, it could be expected that patient compliance could be enhanced through the use of individualized percentages of clinical deterioration over time. The elaboration and validation of the score in a population of patients with diverse characteristics suggest that it could be widely applied in different patient subsets in developing and Western countries.
Study Limitations
In the absence of standardized echocardiographic follow-up, it was not possible to analyze progressive changes in valve function to assess the mitral restenosis rate. However, previous follow-up of this cohort showed that functional deterioration was due to restenosis in 97% of cases. 11 Hemodynamic variables were not included because heart catheterization was not performed after 1993. We did not include alternative measurement of pulmonary artery pressure with Doppler to avoid nonstandardized assessment.
The inclusion of repeat PMC in the composite end point of late functional results may be debated because repeat PMC carries a lower risk than surgery. However, PMC always carries risks of complications and immediate failure. Therefore, repeat PMC and mitral surgery were included in the composite end points of all follow-up studies. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] The generalizability of our scoring system may be limited in the absence of an external validation cohort and by the single-center nature of the study. However, a single-center series ensures more homogeneity in patient assessment and performance of the procedure.
Finally, this model cannot be used to predict long-term outcome according to preprocedural variables alone. Given the major impact of the quality of immediate results on late functional results, such a predictive analysis would ideally need to combine 2 different models respectively predicting immediate and late results.
Conclusions
This series further confirms the long-term efficacy of PMC. In a population of patients with varied characteristics, 30% of them still derive a functional benefit after 20 years. After good immediate results, late deterioration is progressive and strongly determined by age and the quality of immediate results, as assessed by final MVA and final mean gradient. This is the first validated scoring system to be described in the percutaneous treatment of valvular disease, and this simple score enables easy assessment of individual prognosis before hospital discharge, which is of particular relevance given the diversity of candidates for PMC.
